16 September 2014
Patients facing death or irreversible disease progression -– most of whom have exhausted all approved treatment options — sometimes seek access to unapproved and unproven interventions. This type of access, often referred to as “compassionate use,” is unregulated by federal authorities, subject to corporate pharmaceutical policies that change mid-stream, and could potentially adversely affect clinical care in the future, according to preliminary studies.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/9oZc5wrj9H0/140916122856.htm
